A Study to Compare DB-1303/BNT323 Versus T-DM1 in Breast Cancer

PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

228

Participants

Timeline

Start Date

January 29, 2024

Primary Completion Date

February 28, 2026

Study Completion Date

February 28, 2026

Conditions
HER2-positive Breast Cancer
Interventions
DRUG

DB-1303/BNT323

Administered I.V.

DRUG

T-DM1

Administered I.V.

Trial Locations (48)

100039

001, Beijing

100142

010, Beijing

116021

032, Dalian

130021

008, Changchun

130022

038, Jilin

150081

020, Haerbin

200032

002, Shanghai

200120

046, Shanghai

210009

027, Nanjing

210029

004, Nanjing

221006

044, Xuzhou

230001

016, Hefei

230601

029, Hefei

233000

015, Bengbu

250013

031, Jinan

250117

047, Jinan

256603

040, Binzhou

264001

039, Yantai

276003

012, Linyi

300060

021, Tianjin

310003

025, Hangzhou

310016

042, Hangzhou

310022

019, Hangzhou

330006

014, Nanchang

350014

036, Fuzhou

361003

037, Xiamen

410005

030, Changsha

430030

011, Wuhan

430079

009, Wuhan

450003

006, Zhengzhou

450052

005, Zhengzhou

471003

018, Luoyang

510060

023, Guangzhou

510080

024, Guangzhou

510120

026, Guangzhou

516001

028, Huizhou

530021

017, Nanning

022, Nanning

570102

043, Haikou

610041

007, Chengdu

641100

041, Neijiang

644000

034, Yibin

650118

033, Kunming

710061

003, Xi’an

830011

013, Ürümqi

071000

045, Baoding

050011

048, Shijiazhuang

030013

035, Taiyuan

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

BioNTech SE

INDUSTRY

lead

DualityBio Inc.

INDUSTRY